www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma
Xuping Wu1,*, Jing Zhang2,*, Sijun Yang3 , Zhihui Kuang2, Guolei Tan1, Gang Yang1,
Qichun Wei4, Zhigang Guo2
Hat tip to Cheng who posted on YMB Regards, bp Note they thanked Sergi for providing the imetelstat, no mention of Janssen
On line article re radiation and esophageal ca
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
scottmayhew
- Posts: 47
- Joined: Wed Dec 09, 2015 10:26 pm
Re: On line article re radiation and esophageal ca
Doesn't Sergei work for a company Janssen or JnJ acquired?no mention of Janssen
-
biotech_bs
- Posts: 15
- Joined: Wed Jul 13, 2016 1:55 pm
Re: On line article re radiation and esophageal ca
Having a person like Sergei Gryaznov, who is on Imetelstat patents, working for Janssen gives me a lot of added confidence in Geron eventually getting that $65 mil continuation payment from J&J
Re: On line article re radiation and esophageal ca
I deserve no credit, this was turned up by a SA poster. As usual, the question why we didn't do this work in 2003-5.... but it's very encouraging to see that it works on tumor explants as well as in no-feeder-layer cell culture ( a nearly useless screening technique, Vitamin C is the perfect cancer drug... in a dish full of just cancer cells).
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
Re: On line article re radiation and esophageal ca
Thanks, bio. I uploaded it to imetelstat.info.
Have you seen this report from 2012:
Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks
X. Wu et al. (2012)
Telomerase is mainly active in human tumor cells, which provides an opportunity for a therapeutic window on telomerase targeting. We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells. After only 1 week of imetelstat treatment, a reduction of colony formation ability of esophageal cancer cells was observed. This study supports the potential of imetelstat as a therapeutic agent for the treatment of esophageal cancer.
link: https://www.ncbi.nlm.nih.gov/pubmed/22906540 (also on imetelstat.info/pre-clinical then go to '2012 and before')
It seems they have proceeded with this research direction, now confirming the 2012 findings in vivo. Btw: in 2012 Gryaznov was involved in this research.
Have you seen this report from 2012:
Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks
X. Wu et al. (2012)
Telomerase is mainly active in human tumor cells, which provides an opportunity for a therapeutic window on telomerase targeting. We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells. After only 1 week of imetelstat treatment, a reduction of colony formation ability of esophageal cancer cells was observed. This study supports the potential of imetelstat as a therapeutic agent for the treatment of esophageal cancer.
link: https://www.ncbi.nlm.nih.gov/pubmed/22906540 (also on imetelstat.info/pre-clinical then go to '2012 and before')
It seems they have proceeded with this research direction, now confirming the 2012 findings in vivo. Btw: in 2012 Gryaznov was involved in this research.